Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000557520 | SCV000645297 | benign | Amyotrophic lateral sclerosis type 4; Spinocerebellar ataxia, autosomal recessive, with axonal neuropathy 2 | 2022-12-06 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002377107 | SCV002688753 | likely benign | Inborn genetic diseases | 2019-07-11 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Prevention |
RCV004527650 | SCV004110573 | uncertain significance | SETX-related disorder | 2023-02-07 | criteria provided, single submitter | clinical testing | The SETX c.93A>G variant is not predicted to result in an amino acid change (p.=). This variant is predicted to generate a cryptic splice acceptor site within exon 3 (Alamut Visual Plus v1.6.1); however, in silico predictions are imperfect and not equivalent to functional evidence. To our knowledge, this variant has not been reported in the literature. It is reported in 0.0080% of alleles in individuals of African descent in gnomAD (http://gnomad.broadinstitute.org/variant/9-135224723-T-C). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |